Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients

Trial Profile

Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Anastrozole (Primary) ; Everolimus (Primary) ; Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 11 Dec 2014 Trial design presented at the 37th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top